Hydrocision Board of Directors

Mr. Bennett currently serves on the board of directors of several organizations including, SpineMark, CoDon and PAS Asset Acquisition. A 45-year veteran of the medical industry, Lew has held senior executive positions with companies in the orthopedic and spine businesses including, Executive Vice President and Officer-Board Member of NuVasive, Inc.; Executive Vice President and Corporate Officer of Sofamor Danek (now a division of Medtronic, Inc.); President of the General Medical Division of Smith & Nephew; and President of Dillion Manufacturing. In addition, he was one of the founders of Howmedica (now Stryker Orthopedics).

Alastair J.T. Clemow, Ph.D., President and CEO, Nexgen Spine Inc.

Dr. Clemow is currently the President and CEO of Nexgen Spine Inc. He has served in numerous senior management positions including President & CEO of Gelifex, Inc.; Vice President of Worldwide New Business Development at Ethicon Endo-Surgery (a division of Johnson & Johnson); Vice President of New Business Development, Johnson and Johnson Professional Inc.; and Director of R&D, Johnson and Johnson Orthopaedics. Dr. Clemow holds B.Sc. and Ph.D. degrees in Metallurgy from the University of Surrey, and an MBA in Finance from Columbia University.

Dennis B. Costello, Managing Partner, Triathlon Medical Ventures

Dennis Costello brings more than 30 years of industry experience in both
therapeutics and medical devices to Triathlon. He was with Senmed Medical
Ventures from 1996 to 2003, during which he originated and managed early-
and later-stage investments and provided general management for Senmed's
start-up investments. Prior to joining Senmed, Mr. Costello served in
general management and senior marketing and business development positions for both large, public and small, private life science companies, including American Critical Care (a division of American Hospital Supply Corporation), Clonetics Inc., Regent Hospital Products and Hana Biologics. Mr. Costello holds a B.S. degree from the U.S. Naval Academy and an MBA degree from The Harvard Business School.

Douglas J. Daniels, President & CEO, HydroCision

Mr. Daniels has 22 years experience in medical device businesses. He most recently served as CEO of VeinRx, a division of Syntheon LLC. Most of his career was spent at Boston Scientific Corporation, where he held several positions in marketing, business development and sales with the Microvasive Endoscopy Division, culminating in Vice President & General Manager. He has introduced many products to the device market and holds several patents on minimally invasive devices.

Jonathan Fleming, Managing General Partner, Oxford Bioscience Partners

Mr. Fleming is the Managing General Partner of Oxford Bioscience Partners, an international venture capital firm specializing in life science technology-based investments, with offices in Boston and Connecticut. Mr. Fleming has been in the investment business for more than 20 years and has launched and financed growth companies in the United States, Europe, and Israel. Prior to joining OBP in 1996, he was a Founding General Partner of MVP Ventures in Boston. He began his investment career with TVM Techno Venture Management in Munich, Germany. Mr. Fleming is also a co-founder of Medica Venture Partners, a venture capital investment firm specializing in early-stage healthcare and biotechnology companies in Israel. Mr. Fleming is on the board of Asterand plc (LSE: ATD) and is a director of several private companies including Leerink Swann, a Boston-based investment bank specializing in healthcare companies. Mr. Fleming is a Trustee of the Museum of Science in Boston, a Member of the Board of the New England Healthcare Institute, and a Senior Lecturer at the MIT Sloan School of Business. He holds an MPA from Princeton University and a BA from the University of California, Berkeley.

Marc Goldberg , Board of Directors, BioVentures Investors, LLC

Mr. Goldberg co-founded BioVentures Investors with Peter Feinstein in 1999. Since his graduation from Harvard’s elite MBA/JD program in 1983, he has built a remarkable career as industry leader and consummate deal maker at Genetics Institute, the Massachusetts Biotechnology Research Institute, Safer Inc., the Massachusetts Biotechnology Council and, most recently, for the BioVentures portfolio companies. Mr. Goldberg’s achievements at BioVentures include: structuring the transaction and guiding management through the $30M, 4X sale of New Chemical Entities 12 months after its initial investment, closing the sale of Angiolink to Medtronic, producing a 2.7X return over 27 months, selling Ardais to Gulfstream and then guiding the reorganization of Gulfsream into a successful research IT and services business, initiating and driving the restructuring of BioValve into two separate corporate entities, with a significant increase in potential for return on investment. In addition, he has participated in, or served as an advisor on virtually every portfolio-company transaction or financing throughout BioVentures’ investing history.

Richard J. Lim., Omega Fund

With offices in London and Guernsey, the Omega fund is a specialized investment fund providing liquidity to exiting investors in healthcare companies. Omega’s investment focus is the acquisition and subsequent management of direct ownership interests in both U.S. and European public and private biopharmaceutical and medical companies.